Mitogen signaling strength and duration can control cell cycle decisions
Decades ago, mitogen-promoted signaling duration and strength were observed to be
sensed by the cell and to be critical for its decisions: to proliferate or differentiate. Landmark …
sensed by the cell and to be critical for its decisions: to proliferate or differentiate. Landmark …
[HTML][HTML] Advances in cancer therapy: A comprehensive review of CDK and EGFR inhibitors
M Hawash - Cells, 2024 - mdpi.com
Protein kinases have essential responsibilities in controlling several cellular processes, and
their abnormal regulation is strongly related to the development of cancer. The …
their abnormal regulation is strongly related to the development of cancer. The …
Binding Modalities and Phase-Specific Regulation of Cyclin/Cyclin-Dependent Kinase Complexes in the Cell Cycle
Cyclin-dependent kinases (CDKs) are activated upon cyclin-binding to enable progression
through the cell cycle. Dominant CDKs and cyclins in mammalian cells include CDK1 …
through the cell cycle. Dominant CDKs and cyclins in mammalian cells include CDK1 …
Allosteric modulation of NF1 GAP: Differential distributions of catalytically competent populations in loss‐of‐function and gain‐of‐function mutants
Abstract Neurofibromin (NF1), a Ras GTPase‐activating protein (GAP), catalyzes Ras‐
mediated GTP hydrolysis and thereby negatively regulates the Ras/MAPK pathway. NF1 …
mediated GTP hydrolysis and thereby negatively regulates the Ras/MAPK pathway. NF1 …
[HTML][HTML] Palbociclib as an Antitumor Drug: A License to Kill
Neoplastic cells are characterized by uncontrolled cell divisions caused by cell cycle
dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase …
dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase …
The phosphodiesterase-4 inhibitor Zl-n-91 suppresses glioblastoma growth via EGR1/PTEN/AKT pathway
Y Li, X He, S Li, S Chen, Z Zhao, Y Mu, AZ Zhao… - European Journal of …, 2025 - Elsevier
Glioblastoma multiforme (GBM) is a highly heterogeneous and aggressive brain tumor,
which presents significant challenges for treatment in clinical settings. Phosphodiesterase 4 …
which presents significant challenges for treatment in clinical settings. Phosphodiesterase 4 …
[PDF][PDF] Name: Ruth Nussinov, Ph. D.
I Aviv, MD Frederick - ccr.cancer.gov
• Lecture in the Institute Pasteur, Paris; a seminar series given by eminent scientists (2010)•
Invited by the Chairman of the Board of Directors of Forschungszentrum Jülich, and the …
Invited by the Chairman of the Board of Directors of Forschungszentrum Jülich, and the …